Skip to main content

Statute

Hatch-Waxman Act

109 published works

  1. Duane Morris Life Sciences Law

    U.S. Supreme Court Reverses Federal Circuit, Holding No Induced Infringement Plausibly Pled Based on Skinny Label and Related Statements

    By Jason Luo Ph.D.

    By  Jiazhong (Jason) Luo, Ph.D. and Frederick R. Ball Recently, the Supreme Court of the United States unanimously reversed the Federal Circuit in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.,…

  2. Biosimilars Law Bulletin

    Supreme Court’s Unanimous Ruling in Hikma v. Amarin: A Game-Changer for Skinny Label Strategies

    By Aydin H. Harston, Anh-Thu Lam

    The pharmaceutical industry has been watching Hikma Pharmaceutical USA Inc. v. Amarin Pharma, Inc. (No. 24-889) closely for its potentially sweeping implications for generic drug competition, as discussed in our…

  3. Biosimilars Law Bulletin

    Supreme Court Hears Skinny Label Arguments in Hikma v. Amarin, Signaling Impact on Hatch-Waxman Carve-Out Strategy

    By Anh-Thu Lam, Aydin H. Harston

    The Supreme Court heard oral argument on April 29, 2026, in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889), the closely watched skinny-label case for which the Court…

  4. The Patent Playbook

    Supreme Court Hears Oral Argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.: Induced Infringement and “Skinny Labels” at a Crossroads

    By Lena Hughes, Gregory A. Morris, Fangli Chen

    Yesterday, the U.S. Supreme Court heard oral argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, a case that could reshape the landscape of pharmaceutical patent enforcement…

  5. Truth on the Market

    The Fatal Conceit of Cheap Drugs

    By Jeffrey E. Depp

    The U.S. Supreme Court agreed to hear Hikma v. Amarin to answer a narrow question. It may end up saying far more about how policymakers misunderstand pharmaceutical markets. On its…

  6. Duane Morris Life Sciences Law

    U.S. Supreme Court Grants Certiorari in Hikma v. Amarin, Placing “Skinny Label” Inducement in Focus

    By Jason Luo Ph.D.

    On January 16, 2026, the Supreme Court of the United States granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889) to address when induced-infringement liability can attach to…

  7. The Patent Playbook

    Supreme Court Takes Up <em>Hikma v. Amarin</em>: Induced Infringement and Skinny Labels in the Crosshairs

    By Gregory A. Morris, Fangli Chen

    The Supreme Court’s decision to review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. places renewed attention on a familiar but unsettled issue in pharmaceutical patent law: how the induced…

  8. Biosimilars Law Bulletin

    Supreme Court to Address ‘Skinny Label’ Patent Disputes

    By Anh-Thu Lam, Aydin H. Harston

    Introduction On January 16, 2026, the U.S. Supreme Court agreed to hear Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc., a patent dispute that could reshape the landscape of generic…

  9. Patent Law Weblog

    Supreme Court to Resolve Dispute Over Marketing of “Skinny Labeled” Generics

    By Zuhn21b31b8b84f

    By Joshua Rich and Kevin E. Noonan – The Hatch-Waxman Act has always represented a delicate balance between the interests of innovator and generic drugmakers: innovators seek to maintain exclusivity…

  10. Intellectual Property Law Blog

    Claiming A Range, Watch Out For The Presumption Of Obviousness

    By Takuma Nishimura

    This Federal Circuit opinion analyzes the presumption of obviousness and the obviousness challenge based on prior art that describes a wider range of doses than what is claimed. Background Janssen…